⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
globenewswire.com
CORT
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
accessnewswire.com
CORT
Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
globenewswire.com
CORT
La FDA aprobó Lifyorli™ (relacorilant), el antagonista selectivo del receptor de glucocorticoides de Corcept, en combinación con nab-paclitaxel para el tratamiento de pacientes con cáncer de ovario resistente al platino
businesswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT
prnewswire.com
CORT
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
CORT
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
globenewswire.com
CORT
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
globenewswire.com
CORT
Pomerantz LLP Issues Reminder to Shareholders in Corcept Therapeutics Incorporated of Class Action Lawsuit – CORT
accessnewswire.com
CORT
Form 8-K
sec.gov
CORT